Aspira Women’s Health Inc. (NASDAQ:AWH) Short Interest Update

Aspira Women’s Health Inc. (NASDAQ:AWH) was the target of a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 356,900 shares, a decline of 18.6% from the December 15th total of 438,500 shares. Based on an average trading volume of 100,900 shares, the days-to-cover ratio is presently 3.5 days. Approximately 2.9% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Aspira Women’s Health in a report on Sunday. They issued a “hold” rating for the company.

Institutional Trading of Aspira Women’s Health

A hedge fund recently bought a new stake in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co purchased a new position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned about 0.19% of Aspira Women’s Health at the end of the most recent reporting period. Institutional investors and hedge funds own 12.19% of the company’s stock.

Aspira Women’s Health Stock Up 7.5 %

Shares of AWH stock traded up $0.04 during mid-day trading on Thursday, reaching $0.52. The stock had a trading volume of 39,350 shares, compared to its average volume of 85,055. The firm has a market cap of $8.60 million, a PE ratio of -0.43 and a beta of 1.42. Aspira Women’s Health has a one year low of $0.38 and a one year high of $5.65. The firm’s 50 day simple moving average is $0.75 and its 200 day simple moving average is $0.94.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.